Patient Enrollment for TARGET II achieves completion
TARGET II, a prospective, multicenter, single-arm, observed registered clinical trial of Firehawk Raparmacyin Target Eluting Coronary Stent System sponsored by MicroPort Medical (Shanghai) Co., Ltd, completed the patient enrollment process on Feb 13th, 2012. To date, all patient enrollments for the pre-marketing clinical study of Firehawk have been achieved. The clinical study has now entered the clinical follow-up and data-processing stage.
There are three phases in Firehawk pre-marketing clinical investigation study: FIM (First-In-Man), TARGET I and TARGET II. The patient recruitment of FIM was completed in January 2010. 4-month OCT follow-up, 4- and 13-month angiographic follow-ups and 12-month clinical follow-up were then sequentially completed. TARGET I was a prospective, multicenter, randomized controlled clinical trial of Firehawk. The patient enrollment of Target I was completed in May, 2011 and the result of a 9-month angiographic follow-up and 12-month clinical follow-up will be published at TCT2012.
There were a total of 1,261 patents been enrolled in the pre-marketing clinical investigation of Firehawk in China. The clinical trial is a milestone, as it is the first-ever trail in compliance with the SFDA's guidance on Drug-Eluting Coronary Stents Systems:-Clinical Studies (Draft). It is also the largest clinical study on drug eluting coronary stent systems that ever been conducted in China.
Privacy settings
This website may store cookies on your browser. Cookies are mostly used to make the website work as you expect it to. No cookie will directly identify you, but it can give you a more personalized browsing experience.
MicroPort respects your privacy rights, so you can block some types of cookies. Technically non-essential cookies and tracking mechanisms, that enable us to provide you with customized offers (marketing cookies), are only used if you have given prior consent to such use.
By clicking “Save”, only the cookies you selected will be used. You can withdraw the consent that you granted here at any time by going to Cookies Settings.
For more information, please see our Cookie Policy.